Omega-3 and vitamin D supplements tied with lesser hospitalizations in HF patients

Written By : Dr. Shravani Dali |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2022-04-11T20:15:36+05:30 | Updated On 11 April 2022 8:35 PM IST

A study published in JACC: Heart Failure suggested that patients with and without type 2 diabetes who took omega-3 and vitamin D supplements were less likely to be hospitalized for heart failure, compared with those who took placebos.

The primary aim was to evaluate whether prevalent type 2 diabetes (T2D) modifies the effects of omega-3 supplementation on heart failure (HF) hospitalization. The secondary aim was to examine if race modifies the effects of omega-3 supplements on heart failure (HF) risk.

It is unclear whether race and type 2 diabetes (T2D) modify the effects of omega-3 supplementation on the incidence of HF. In this ancillary study of the parent VITAL (Vitamin D and Omega-3 Trial)—a completed randomized trial testing the efficacy of vitamin D and omega-3 fatty acids on cardiovascular diseases and cancer, we assessed the role of type 2 diabetes (T2D) and race on the effects of omega-3 supplements on the incidence of heart failure (HF) hospitalization (adjudicated by a review of medical records and supplemented with a query of Centers for Medicare and Medicaid Services data).

The results of the study are:

When omega-3 supplements were compared with placebo, the HR for first HF hospitalization was 0.69 in participants with prevalent type 2 diabetes (T2D) and 1.09 in those without type 2 diabetes (T2D)
Furthermore, prevalent type 2 diabetes (T2D) modified the effects of omega-3 fatty acids on the incidence of recurrent heart failure (HF) hospitalization
In their secondary analysis, omega-3 supplementation reduced recurrent heart failure hospitalization only in Black participants

Thus, the data show beneficial effects of omega-3 fatty acid supplements on the incidence of heart failure (HF) hospitalization in participants with type 2 diabetes (T2D) but not in those without type 2 diabetes (T2D), and such benefit appeared to be stronger in Black participants with type 2 diabetes (T2D).

Reference:

Diabetes Mellitus, Race, and Effects of Omega-3 Fatty Acids on Incidence of Heart Failure Hospitalization by Luc Djoussé et. al published in the JACC: Heart Failure.

https://www.sciencedirect.com/science/article/abs/pii/S2213177922000543?via=ihub

JACC: Heart Failureheart failurehospitalizationomega-3 fatty acidssupplementstype-2 diabetesvitamin d

Source : JACC: Heart Failure

Dr. Shravani Dali

Dr. Shravani Dali has completed her BDS from Pravara institute of medical sciences, loni. Following which she extensively worked in the healthcare sector for 2+ years. She has been actively involved in writing blogs in field of health and wellness. Currently she is pursuing her Masters of public health-health administration from Tata institute of social sciences. She can be contacted at editorial@medicaldialogues.in.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751